Patents Examined by Dennis Heyer
-
Patent number: 11213509Abstract: The present invention relates, in certain embodiments, to methods for preventing and/or treating neurodegenerative damage (e.g., secondary cascade of neurodegenerative damage) and improving functional outcomes (e.g., outcomes associated with cognitive, behavior and sensorimotor function) caused by traumatic brain injury using neuroprotective lipoyl compounds. The present invention also provides, in various embodiments, compositions for use in treating and/or preventing TBI in a subject in need thereof, compounds for use in the manufacture of a medicament for treating and/or preventing TBI in a subject in need thereof, and methods of preparing a pharmaceutical composition for treating and/or preventing secondary brain damage caused by TBI.Type: GrantFiled: July 30, 2020Date of Patent: January 4, 2022Assignee: ISCHEMIX, LLCInventors: Alexander Baguisi, Reinier Beeuwkes, Ralph Casale, David A. DeWahl, Jr., Steven A. Kates, Alan S. Lader
-
Patent number: 11214536Abstract: The present invention relates to new polymorphs of LXR? agonists which exhibit improved physical properties. The invention also relates to pharmaceutical compositions including a pharmaceutically effective amount of an LXR? agonist, as well as methods of treating cancer including administration of a formulation including an LXR? agonist to a subject in need thereof.Type: GrantFiled: November 20, 2018Date of Patent: January 4, 2022Assignee: Inspirna, Inc.Inventors: Saurabh Chitre, Hayley Reece, Stephen Wald
-
Patent number: 11191761Abstract: Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.Type: GrantFiled: May 13, 2016Date of Patent: December 7, 2021Assignees: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES, SHANGHAI ACEBRIGHT PHARMACEUTICALS CO., LTD.Inventors: Shiyan Guo, Yong Gan, Ao Zhang, Zehong Miao, Li Gao, Jian Ding
-
Patent number: 11191753Abstract: The present invention provides a physically and chemically stable pharmaceutical liquid composition including sodium picosulfate, magnesium oxide, citric acid and malic acid and methods of making and using such a composition.Type: GrantFiled: April 13, 2020Date of Patent: December 7, 2021Assignee: FERRING INTERNATIONAL CENTER SA.Inventors: Bong Gil Nam, Byeung Jun Lee, Shunji Jin
-
Patent number: 11185518Abstract: Ketogenic compositions include a mixture of optically pure S-beta-hydroxybutyrate salts and acid(s) or non-racemic mixture of beta-hydroxybutyrate salts and acid(s) enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contains from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.Type: GrantFiled: February 6, 2020Date of Patent: November 30, 2021Assignee: AXCESS GLOBAL SCIENCES, LLCInventor: Gary Millet
-
Patent number: 11180466Abstract: The invention relates to a compound of general formula (I): wherein R1, R2, R3, R4, Q, m and n are as defined herein. The compounds are inhibitors of Bcl-3 and are useful for the treatment of cancer, particularly metastatic cancer.Type: GrantFiled: October 4, 2019Date of Patent: November 23, 2021Assignee: UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITEDInventors: Andrew David Westwell, Andrea Brancale, Richard William Ernest Clarkson, Jitka Soukupova
-
Patent number: 11179385Abstract: Compositions and methods for treatment of viral skin disease, precancerous and cancerous skin disease, and other neoplasms are disclosed.Type: GrantFiled: June 30, 2016Date of Patent: November 23, 2021Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: Xiaowei Xu, Shujing Liu, Alain Rook, Pankaj Karande
-
Patent number: 11179389Abstract: The instant invention provides compounds of formula I which are PI3K-delta inhibitors, and as such are useful for the treatment of PI3K-delta-mediated diseases such as inflammation, asthma, COPD and cancer.Type: GrantFiled: December 12, 2018Date of Patent: November 23, 2021Assignee: Merck Sharp & Dohme Corp.Inventors: Meredeth A. McGowan, Jason D. Katz, Hua Zhou, David James Witter, Chaomin Li, Kathryn A. Lipford, Joey L. Methot, Abdelghani A. Achab, Xavier Fradera, Shimin Xu, Jianmin Fu
-
Patent number: 11173118Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.Type: GrantFiled: March 16, 2020Date of Patent: November 16, 2021Assignee: Heron Therapeutics, Inc.Inventors: Thomas B. Ottoboni, Han Han
-
Patent number: 11174220Abstract: The present invention relates to metal salts of 2-[3-[(3R)-3-[[2-chloro-3-(trifluoromethyl)phenyl]methyl-(2,2-diphenylethyl)amino]butoxy]phenyl]acetic acid which exhibit improved physical properties and stability. The invention also relates to pharmaceutical compositions including an effective amount of the metal salts, as well as methods of treating cancer including administration of a pharmaceutical composition including a salt of the invention to a subject in need thereof.Type: GrantFiled: December 11, 2020Date of Patent: November 16, 2021Assignee: Inspirna, Inc.Inventors: Stephen Wald, Eduardo J. Martinez, Samuel Stratford, Amanda Buist, Joseph Benson, Jonathan Loughrey
-
Patent number: 11166934Abstract: The present invention relates to a pharmaceutical composition for preventing or treating allergic diseases such as asthma or atopy including baicalein as an active ingredient. Baicalein is capable of regulating thymic stromal lymphopoietin-mediated signal transduction. The pharmaceutical composition of the present invention can effectively suppress inflammatory responses of allergic or asthmatic diseases due to the presence of baicalein extracted from Scutellariae Radix that regulates TSLP-mediated intracellular signal transduction to inhibit intracellular phosphorylation of STATS and inhibit the binding of TSLP to TSLPR. In addition, the pharmaceutical composition of the present invention may further include one or more compounds having synergistic effects with baicalein. In this case, the pharmaceutical composition can more effectively suppress inflammatory responses of allergic diseases such as asthma or atopy.Type: GrantFiled: January 4, 2018Date of Patent: November 9, 2021Assignee: Azcuris Co., Ltd.Inventors: Ki Yong Lee, Young Ho Jeon, Youngjoo Byun, Kiho Lee, Yong Woo Jung
-
Patent number: 11160867Abstract: The present disclosure provides veterinary formulations comprising a therapeutically effective amount of an antiprotozoal compound and a polymer. The disclosure also provides methods of treating trichomoniasis in a bovine and methods of treating a Tritrichomonas foetus infection in a bovine utilizing the veterinary formulations.Type: GrantFiled: May 11, 2018Date of Patent: November 2, 2021Assignee: AUBURN UNIVERSITYInventor: Sue H. Duran
-
Patent number: 11160785Abstract: The invention relates to compositions comprising a synaptic vesicle glycoprotein 2A (SV2A) inhibitor in an extended release and an acetylcholinesterase inhibitor (AChEIs). The invention also relates to using such compositions in treating cognitive impairment associated with central nervous system disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), dementia, Alzheimer's Disease (AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease (PD), autism, compulsive behavior, and substance addiction.Type: GrantFiled: March 14, 2014Date of Patent: November 2, 2021Assignee: AgeneBio Inc.Inventor: Gardiner Smith
-
Patent number: 11154549Abstract: The invention provides pharmaceutical compositions comprising macromolecular gastrointestinal enzyme-labile opioid prodrugs, co-formulated with small-molecule and/or macromolecular gastrointestinal enzyme inhibitors. The macromolecular constructs are minimally absorbed from the GI tract, and can produce non-linear pharmacokinetic profiles of the delivered opioid agonist following oral ingestion. An optional macromolecular opioid antagonist may also be present in compositions of the invention to discourage tampering by potential abusers.Type: GrantFiled: April 17, 2019Date of Patent: October 26, 2021Assignee: ELYSIUM THERAPEUTICS, INC.Inventor: Thomas E. Jenkins
-
Patent number: 11135295Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: GrantFiled: February 4, 2021Date of Patent: October 5, 2021Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau
-
Patent number: 11135158Abstract: A medicated hard candy product for treating eosinophilic esophagitis (EoE) is disclosed herein. The medicated hard candy product includes a hard candy base material, the hard candy base material forming a substantially rigid candy product after being heated and permitted to cool for a predetermined time period; and a corticosteroid, the corticosteroid being intermixed with the hard candy base material. The medicated hard candy product is configured to reduce or alleviate esophageal inflammation and/or symptoms associated therewith in an individual when orally administered thereto. In one or more embodiments, the corticosteroid comprises one of: (i) budesonide, (ii) fluticasone, (iii) ciclesonide, (iv) beclomethasone dipropionate, and (v) mometasone furoate. Also, in one or more embodiments, the medicated hard candy product is in the form of a lollipop or lozenge.Type: GrantFiled: October 12, 2018Date of Patent: October 5, 2021Inventor: Michael Lee Martin
-
Patent number: 11129825Abstract: The invention provides compositions and methods for the treatment or prevention of pain. The invention provides constructs whereby hydrolysis of the construct by a specified gastrointestinal enzyme directly, or indirectly, releases an opioid when taken orally as prescribed. The gastrointestinal enzyme mediated release of opioid from constructs of the invention is designed to be attenuated in vivo via a saturation or inhibition mechanism when overdoses are ingested. The invention further provides constructs that are highly resistant to oral overdose, chemical tampering, and abuse via non-oral routes of administration.Type: GrantFiled: February 26, 2019Date of Patent: September 28, 2021Assignee: ELYSIUM THERAPEUTICS, INC.Inventor: Thomas E. Jenkins
-
Patent number: 11129827Abstract: Provided herein are compounds and pharmaceutical compositions comprising said compounds useful as modulators of MAGL and/or FAAH. The subject compounds and compositions are useful for the treatment of pain and neurological disorders.Type: GrantFiled: June 4, 2019Date of Patent: September 28, 2021Assignee: Abide Therapeutics, Inc.Inventors: Cheryl A. Grice, Justin S. Cisar, Katharine K. Duncan, Yu Feng, John J. M. Wiener, Olivia D. Weber
-
Patent number: 11129895Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: GrantFiled: February 2, 2021Date of Patent: September 28, 2021Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau
-
Patent number: 11123431Abstract: Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.Type: GrantFiled: February 8, 2021Date of Patent: September 21, 2021Assignee: AXSOME THERAPEUTICS, INC.Inventor: Herriot Tabuteau